Mycobacterial Infections Potentiated by Biologics.

Link to article at PubMed

Mycobacterial Infections Potentiated by Biologics.

Infect Dis Clin North Am. 2020 Jun;34(2):413-423

Authors: Calabrese C, Winthrop KL

Biologic therapies have revolutionized the treatment of immune-mediated inflammatory diseases but are associated with an increased risk of serious and opportunistic infections, including tuberculosis and nontuberculous mycobacterial disease. Despite this increased risk, the overall risk-benefit ratio remains favorable with appropriate screening and risk assessment. Further population-based studies are needed to establish the risk of tuberculosis and nontuberculous mycobacterial disease with the new biologics. This article highlights the incidence and drug-specific risk of tuberculous and nontuberculous mycobacterial infection in the setting of biologics, screening and prevention, and treatment of latent tuberculosis in this setting.

PMID: 32444014 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *